C02-FolfoxResponse: screen personalized alternative treatments for subgroups of FOLFOX resistant colorectal cancer
FOLFOX is a chemotherapy regimen. FOLFOX is used to treat colorectal cancer. The observed objective response to FOLFOX in metastatic colorectal cancer is ~50%. Carbon Logic Biotech C02-FolfoxResponse aims to identify subgroups of FOLFOX resistant patterns and screen personalized alternative treatments:
(1) C02-FolfoxResponse predicts response to FOLFOX treatment
(a) FOLFOX treated stage 4 colorectal cancer patients with objective response: sensitivity of 97.6% and a specificity of 100%.
(b) FOLFOX treated stage 4 colorectal cancer patients: HR=2.6, pvalue=0.02(Figure 1A).
(c) FOLFOX treated epithelial-mesenchymal transition subtype stage 3 colorectal cancer patients: HR=2.36, pvalue=0.02(Figure 1B).
|
Figure 1A.
|
|
Figure 1B.
|
|
|
(2) We investigate PARP inhibitors+FOLFOX as an alternative treatment for the IML1 subgroup of FOLFOX nonresponders(red box, right panel, Figure 2).
Figure 2. screen alternative treatments for subgroups of FOLFOX nonresponders
Sun Tian. et al., (2021) Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients. Cancer Investigation.
DOI: 10.1080/07357907.2020.1843662. PMID: 33258714
